Zobrazeno 1 - 10
of 30
pro vyhledávání: '"David S Lakomy"'
Autor:
David S. Lakomy, Juliana Wu, Dorothy Lombe, Emmanouil Papasavvas, Susan Citonje Msadabwe, Yimin Geng, Luis J. Montaner, Elizabeth Chiao, Lilie L. Lin
Publikováno v:
Cancer Medicine, Vol 10, Iss 13, Pp 4206-4220 (2021)
Abstract Background Immune markers have been correlated with prognosis in a variety of solid tumors, including cervical cancer. Objective To review the literature on hematologic and immune markers and their association with recurrence and survival am
Externí odkaz:
https://doaj.org/article/e855cd46b0c34159af90a19aa6c9f343
Autor:
Alison K. Yoder, David S. Lakomy, Yongquan Dong, Suchismita Raychaudhury, Kathryn Royse, Christine Hartman, Peter Richardson, Donna L. White, Jennifer R. Kramer, Lilie L. Lin, Elizabeth Chiao
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-17 (2021)
Abstract Background The incidence of anal squamous cell carcinoma has been increasing, particularly in people living with HIV (PLWH). There is concern that radiosensitizing drugs, such as protease inhibitors, commonly used in the management of HIV, m
Externí odkaz:
https://doaj.org/article/f9ddcb56eb8d40319a35773b6a63089c
Autor:
Zhen Lu, Weiqun Mao, Hailing Yang, Janice M. Santiago-O’Farrill, Philip J. Rask, Jayanta Mondal, Hu Chen, Cristina Ivan, Xiuping Liu, Chang-Gong Liu, Yuanxin Xi, Kenta Masuda, Eli M. Carrami, Meng Chen, Yitao Tang, Lan Pang, David S. Lakomy, George A. Calin, Han Liang, Ahmed A. Ahmed, Hariprasad Vankayalapati, Robert C. Bast Jr.
Publikováno v:
The Journal of Clinical Investigation, Vol 132, Iss 11 (2022)
Poly(ADP-ribose) polymerase inhibitors (PARP inhibitors) have had an increasing role in the treatment of ovarian and breast cancers. PARP inhibitors are selectively active in cells with homologous recombination DNA repair deficiency caused by mutatio
Externí odkaz:
https://doaj.org/article/2135cd9f007a441e941965d7b77e03eb
Autor:
Lilie L. Lin, David S. Lakomy, Elizabeth Y. Chiao, Robert M. Strother, Meg Wirth, Ethel Cesarman, Margaret Borok, Naftali Busakhala, Carla J. Chibwesha, Lameck Chinula, Ntokozo Ndlovu, Jackson Orem, Warren Phipps, Vikash Sewram, Samantha L. Vogt, Joseph A. Sparano, Ronald T. Mitsuyasu, Susan E. Krown, Satish Gopal
Publikováno v:
JCO Global Oncology, Vol , Iss 6, Pp 1134-1146 (2020)
PURPOSEThe aim of this study was to review the current status of clinical trials for HIV-associated malignancies in people living with HIV in sub-Saharan Africa (SSA) and efforts made by the AIDS Malignancy Consortium (AMC) to build capacity in SSA f
Externí odkaz:
https://doaj.org/article/79b9238cbebd496bbde3be934652fcc7
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 21, Iss , Pp 56-61 (2020)
Summary: PARP inhibitors have been shown to radiosensitize tumor cells in both in vitro and in vivo studies. This is a phase I study that aims to determine the safety, tolerability, and maximally tolerated dose of talazoparib, a PARP inhibitor, when
Externí odkaz:
https://doaj.org/article/108cdba88931415abe6d292541ecc779
Publikováno v:
Gynecologic Oncology Reports, Vol 33, Iss , Pp 100581- (2020)
Externí odkaz:
https://doaj.org/article/a55e32f0f2d042e4a3cf4a3d067ad06c
Autor:
David S Lakomy, Alison K Yoder, Juliana Wu, Mike Hernandez, Martins Ayoola-Adeola, Anuja Jhingran, Ann Klopp, Pamela Soliman, Susan K Peterson, Lilie L Lin
Publikováno v:
International Journal of Gynecologic Cancer. 32:1266-1275
ObjectivePelvic floor dysfunction is a common adverse effect of uterine cancer treatment. In this study we compared patient-reported outcomes regarding pelvic floor dysfunction among uterine cancer survivors after hysterectomy and bilateral salpingo-
Autor:
David S. Lakomy, Juliana Wu, Bhavana V. Chapman, Zhiqian Henry Yu, Belinda Lee, Ann H. Klopp, Anuja Jhingran, Patricia J. Eifel, Lilie L. Lin
Publikováno v:
Pract Radiat Oncol
PURPOSE: This study aimed to validate the safety of paraaortic nodal (PAN) radiation therapy (RT) for patients with cervical cancer when the duodenal dose is limited to V(55) < 15 cm(3) and V(60) < 2 cm(3). METHODS AND MATERIALS: A total of 97 patien
Outcomes After Breast Radiation Therapy in a Diverse Patient Cohort With a Germline BRCA1/2 Mutation
Autor:
Jennifer K. Litton, Isabelle Bedrosian, Bhavana V. Chapman, Shane R. Stecklein, Michael C. Stauder, Yu Shen, Eric A. Strom, David S. Lakomy, George H. Perkins, Karen E. Hoffman, Scott J. Bright, Simona F. Shaitelman, Wendy A. Woodward, Angelica M. Gutierrez Barrera, Gabriel O. Sawakuchi, Banu Arun, Oluwafikayo O. Olamigoke, Diane Liu, Benjamin Smith
Publikováno v:
Int J Radiat Oncol Biol Phys
Purpose BRCA1/2 pathogenic variant (PV) mutations confer radiation sensitivity preclinically, but there are limited data regarding breast cancer outcomes after radiation therapy (RT) among patients with documented BRCA1/2 PV mutations versus no PV mu
Autor:
Jennifer R. Kramer, Yongquan Dong, Christine Hartman, Donna L. White, Kathryn E. Royse, David S. Lakomy, Suchismita Raychaudhury, Peter Richardson, Alison Yoder, Lilie L. Lin, Elizabeth Y. Chiao
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-17 (2021)
BMC Cancer
BMC Cancer
BackgroundThe incidence of anal squamous cell carcinoma has been increasing, particularly in people living with HIV (PLWH). There is concern that radiosensitizing drugs, such as protease inhibitors, commonly used in the management of HIV, may increas